Cellectis

Senior Director, Medical Monitor, Hematology-Oncology

Cellectis  •  $240k/yr  •  New York (Hybrid)  •  4 months ago
Apply
AI can make mistakes so check important info. Chat history is never stored.

Job Description

Senior Director, Medical Monitor, Hematology–Oncology

Location: New York, NY (Hybrid)
Department: Clinical Development – Clinical Sciences
Reports to: Chief Medical Officer

About Cellectis

Cellectis is a clinical‑stage biotechnology company developing off‑the‑shelf UCART® allogeneic CAR‑T therapies to create a future where gene‑edited cell therapies are accessible to all patients who need them. Driven by innovation, scientific rigor, and a commitment to patients, we are advancing a pipeline designed to transform the treatment landscape across hematologic malignancies.

We are seeking a Senior Director, Medical Monitor with deep Hematology/Oncology expertise to join our Clinical Sciences team and help shape the next generation of UCART therapies.

The Senior Director, Medical Monitor serves as a senior medical and scientific leader within the Clinical Development organization. In this role, you will guide clinical strategy, lead medical oversight for clinical studies, and partner cross‑functionally to ensure the successful execution of Cellectis’ clinical‑stage programs. You will be a key contributor to trial design, safety evaluation, regulatory interactions, and data interpretation across the UCART portfolio.

Key Responsibilities

  • Serve as the primary medical monitor for assigned studies, ensuring patient safety and scientific integrity.
  • Provide real‑time medical guidance to investigators, internal teams, and regulatory authorities.
  • Lead ongoing review of safety data, including AEs/SAEs, emerging trends, and risk assessments.
  • Partner closely with Pharmacovigilance to ensure comprehensive safety oversight.
  • Contribute to the design and planning of UCART clinical programs with a deep understanding of heme‑onc diseases.
  • Support indication prioritization, competitive landscape assessments, and long‑range development planning.
  • Collaborate with Translational Science, Regulatory, and Clinical Operations to align clinical strategy across programs.
  • Provide senior clinical leadership from trial startup through closeout.
  • Participate in site feasibility, investigator engagement, and recruitment strategies.
  • Lead investigator calls and contribute to medical case discussions.
  • Develop clinical content for protocol documents, ICFs, training materials, and study governance reviews.
  • Represent Cellectis in interactions with FDA, EMA, and global health authorities
  • Contribute to regulatory submissions including IBs, DSURs, PSURs, CSRs, and responses to agency questions.
  • Build and maintain relationships with KOLs, cooperative groups, and clinical investigators.
  • Lead preparation of internal and external clinical presentations, including for DSMBs, investigator meetings, and conferences.
  • Contribute to abstracts, posters, and peer‑reviewed manuscripts.
  • Ensure clear, accurate, and scientifically rigorous communication across all clinical deliverables.
  • Support the evolution of Cellectis’ clinical development processes, tools, and best practices.
  • Contribute to portfolio‑wide initiatives and organizational growth.

Education and Experience

  • MD or DO required
  • Board certification/eligibility in Hematology and/or Oncology strongly preferred
  • 10–15+ years in pharma/biotech, academic clinical research, or equivalent environment.
  • 6+ years as a Medical Monitor in interventional clinical trials.
  • Proven experience in:
    • Safety monitoring and AE/SAE assessment
    • Clinical data review
    • Regulatory interactions and submissions
  • Strong understanding of cGCP and global clinical development processes.

Core Competencies

  • Excellent clinical judgment and decision‑making skills.
  • Strong interpersonal and communication skills, with the ability to influence cross‑functional teams.
  • Demonstrated ability to build strong partnerships with investigators, KOLs, and internal stakeholders.
  • Outstanding scientific writing and presentation skills.
  • Comfortable in a fast‑paced, innovative biotech environment
  • Ability to travel up to 20%

Compensation Range: $240k-275k

Cellectis

About Cellectis

Cellectis is a global clinical-stage biopharmaceutical company. Pioneers and innovators in our field, our mission is to develop innovative treatments for patients with unmet medical needs.

With 25 years of expertise, we have the best-in-class gene editing platform focusing on immuno-oncology, and gene therapy. Through our efficient and precise TALEN® technology, we create allogeneic CAR-T cells capable of recognizing and combating cancer cells.

Today, our two* clinical programs target patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma (NHL).

We are fully integrated and a leader in end-to-end gene editing, allogeneic CAR T-cell companies. With our in-house manufacturing, we control our gene and cell therapy process from start to finish with starting materials produced in Paris (France) and CAR-T therapy products created in Raleigh, NC.

We also have several ongoing strong collaborations, based on our TALEN® technology, with leading cell & gene therapy companies, including our recent partnership with AstraZeneca, to develop new product candidates in oncology, immunology, and treatment of rare diseases.

At Cellectis, we are committed to a cure.

Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).

To find out more about us, visit our website: www.cellectis.com. To learn more about our community guidelines, visit: http://www.cellectis.com/en/social-media-guidelines/

Follow our other social media account on X.

(*) On November 4, 2024, Cellectis decided to focus its current development efforts on the BALLI-01 and NATHALI-01 studies and therefore to deprioritize the development of UCART123.

TALEN® is a registered trademark owned by the Cellectis Group.

Industry
Biotech & Life Sciences
Company Size
201-500 employees
Headquarters
Paris, FR
Year Founded
1999
Social Media